In this article, I will explore the complexity of lung cancer and why it is classed as one of the most deadly cancers. As well as this, I will explain how different types of lung cancer are classified depending on the cells present in tumours and how the classification affects the treatment a patient is given. Furthermore, I will look at the current treatments for lung cancer and how they are used. And last but not least, I will explain what Circulating Tumor Cells (CTCs) are and how they may be able to help scientists diagnose and treat lung cancer in the near future.
Matrix metalloproteinases (MMPs) are enzymes that are highly expressed in tumours and are thought to have an important role in the advancement of cancer. Of particular interest is their contribution to metastasis – the spread of cancer around the body. As a result, they are currently being researched with the endeavour to develop new anticancer agents, with inhibitors of MMPs considered to be a viable option for future use in chemotherapy. Furthermore, these enzymes could be used to improve the way in which the body metabolises anti-cancer drugs, a method in which the drugs are only activated in the presence of MMPs in the tumour, and so reducing the potential for harmful side effects.